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OBJECTIVE: To identify the factors associated with the prescription of vaginal pessaries (VPs) as a conservative
treatment for pelvic organ prolapse (POP).
METHODS: A cross-sectional study was performed during two annual urogynecology and general obstetrics and
gynecology meetings in 2017 (Sa˜o Paulo, SP, Brazil). A 19-item deidentified questionnaire regarding experiences
and practices in prescribing VPs for POP patients was distributed among gynecologists. Our primary outcome
was the frequency of prescribing VPs as a conservative treatment for POP. The reasons for prescribing or not
prescribing VPs were also investigated. Univariate and multivariate analyses with crude and adjusted odds ratios
(ORs) were performed for variables associated with the prescription of pessaries.
RESULTS: Three hundred forty completed surveys were analyzed. Half of the respondents (53.53%) were
between 30-49 years old; most of them were female (73.53%), were from the Southeast Region (64.12%), were
trained in obstetrics and gynecology (80.24%) or urogynecology (61.18%) and worked in private offices
(63.42%). More than one-third (36.48%) attended four or more POP cases/week, and 97.65% (n=332) had heard
or knew about VPs for POP; however, only 47.06% (n=160) prescribed or offered this treatment to patients.
According to the multivariate analysis, physicians aged 18-35 years (OR=1.97[1.00-3.91]; p=0.04), those who
participated in a previous urogynecology fellowship (OR=2.34[1.34-4.09]; po0.01), those with relatively high
volumes of POP cases (4 or +) (OR=2.23[1.21-4.47]; p=0.01) and those with PhD degrees (OR=2.75[1.01-7.54];
p=0.05) prescribed more pessaries.
CONCLUSIONS: Most gynecologists did not prescribe VPs. Younger physician age, participation in a previous
urogynecology fellowship, a PhD degree, and a relatively high volume of POP cases were associated with
increased VP prescription rates.
KEYWORDS: Survey; Pessary; Pelvic Organ Prolapse; Gynecologists; Practice; Knowledge.
’ INTRODUCTION
Pelvic organ prolapse (POP) is a common and increasingly
prevalent disease in adult and elderly women (1). Surgical
treatment is the definitive treatment for this disease; however,
for patients who do not want to undergo surgery (or have a
high anesthetic risk), life-style adjustment, physical therapy
and the use of vaginal pessaries (VPs) are possibilities that
should be offered as initial treatment options (2). Among the
three latter conservative treatments, VPs provide high sub-
jective cure rates (60-80%) (3). Moreover, a systematic review
demonstrated that VPs produced a positive effect on the quality
of life women (4).
However, there are controversies among physicians regard-
ing the appropriate use of pessaries (5). There are also regional
differences in the practice of prescribing VPs; a published
survey performed by members of the International Urogyne-
cological Association (IUGA) showed that South America was
ranked fourth regarding the consistent or frequent offering of
VPs according to 49% of the respondents (6). This value was
considered low when compared to North America (87.5%),
and to our knowledge, this is only survey to evaluate pessary
prescription in South America. In Europe, a nationwide
survey in the Netherlands found that 69% of gynecologists
with special interest in urogynecology proposed pessary treat-
ment for their patients, and 13% had a written protocol for VP
prescription in their department (7). Unfortunately, in Brazil,
the public health system does not provide VPs for patients,
and we do not have information about whether women are
counseled about conservative options. Thus, ignorance about
the prescribing patterns of VPs in Brazil by physicians has
contributed to the suboptimal education of patients regardingDOI: 10.6061/clinics/2019/e934
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their options for treating POP, and physicians may not pro-
vide the best option for all kinds of clinical scenarios. It is
important to understand the factors associated with VP pres-
cription so that this treatment may be considered an option by
health care providers.
’ METHODS
This was a cross-sectional study (survey) performed during
two meetings (Jornada de Uroginecologia da FMUSP – April
2017; Congresso da Associac¸ão de Obstetrícia e Ginecologia
do Estado de São Paulo – August 2017). As physicians were
visiting the exhibition area, they were invited to participate
in the survey. Medical residents and attending physicians
were eligible to participate. The Institutional Review Board of
the University of Campinas approved this survey (CAAE
61607416.0.0000.5404).
After explaining the aims of the survey, the participants
read and signed an informed consent form. Then, a 19-item,
deidentified questionnaire (to reduce attrition and observer
bias) about practices and knowledge of pessary management
was provided to them. One hundred respondents from the
first meeting participated, and 240 respondents from the
second meeting responded. This questionnaire was devel-
oped specifically for this survey, and although it was not
previously pilot tested, it was elaborated by a panel of two
coauthors; one of them was an expert in urogynecology
(C.R.T. J) and the other was a physiotherapist with a specia-
lization in pelvic floor dysfunctions (S.A.C). The primary
outcome was whether the physician offered or prescribed a
VP as a treatment option for patients (yes/no). The depen-
dent variables were the characteristics of the gynecologists
(age, sex, educational level), settings where they attended
to patients, reasons for not prescribing or indicating VPs,
management of VPs and complications associated with VPs.
We asked the participants to reply the questions as if con-
sidering a patient without a previous pessary fitting trial.
A sample size calculation was performed. Previous studies
found a prevalence of VP prescription of 60-80% (5,7); consi-
dering an absolute estimate of 10% and a significance level
of 5%, the minimum sample size was between 81 and 92
patients. Descriptive data were analyzed using SAS version
9.2 (SAS Institute, Cary, NC, USA). The frequencies and
percentages of respondents were calculated. Chi-square tests
were performed to analyze the association between the
dichotomous variables and Student’s t-tests were performed
for the continuous variables. Chi-square tests for trends were
performed to determine whether there were any correlations
between the number of attended POP cases or educational
level with prescribing or not prescribing VPs. A univariate
analysis to calculate a crude odds ratio (OR) was performed
if the p-value waso0.05; a multivariate analysis was perfor-
med for all the variables with a p-value o0.15. Missing
data was not supplemented with any imputation methods.
The significance level was stipulated as 5%.
’ RESULTS
Three hundred forty physicians completed the survey. The
mean age of the interviewed gynecologists was 40.49±11.44
years (20-70), and most of the physicians were women
(73.53%) from the Southeast Region (64.12%) of Brazil.
Regarding the education level, 250 (73.52%) physicians had
concluded a medical residency in obstetrics and gynecology,
and 60.88% had participated in a clinical fellowship in
urogynecology. The most frequent types of departments that
physicians were affiliated were private offices (63.42%) and
public hospitals (45.43%). More than 90% (n=318) reported
that they attended POP cases, with a frequency of four or
more patients per week (36.28%).
Almost the entire sample (n=331; 97.35%) answered that
they knew or heard about VPs (Table 1); however, when they
were asked if they prescribed or offered the use of VPs for
patients, 52.94% said that they did not. The most frequent
reason for not prescribing VPs was that they did not have
experience (90.56%). On the other hand, most of the VP pres-
cribers said they often offer the device to patients (57.84%);
a ring pessary was the most frequently prescribed type
(54.19%), followed by a donut pessary (48.39%). The most
frequent reasons for prescribing VPs were that women had
no surgical conditions (89.03%), followed by advanced age
(68.39%). The mean age of the group of VP prescribers
(39.50±10.94) was almost two years younger than the mean
age of the VP nonprescribers (41.42±11.84), with no
significant difference (p=0.12). Sex (p=0.12), region (p=0.83)
and education level (p=0.34) were not associated with
prescribing/offering VPs to patients.
Most of the physicians scheduled patients for monthly
follow-ups for VP cleaning and management (70.32%), and
replacement of the device usually occurred when the patient
requested it (41.18%) or after one year of use (26.80%). How-
ever, most gynecologists counseled women on to clean their
pessaries at home (89.68%). More than 80% of the physicians
advocated the use of vaginal estrogen with a VP. With regard
to complications with the use of VPs, more than half of the
prescribers (54.84%) said they observed some complications
such as increased vaginal discharge (69.41%) or malodorous
discharge (35.29%). Finally, the majority (73.55%) indicated
that a VP is a good alternative for POP treatment.
Table 2 presents the univariate and multivariate analysis
of the risk factors. Physicians between the ages of 18 and
35 years (OR=1.81[1.03-3.21]; p=0.04), those who participated
in a previous urogynecology fellowship (OR=3.97[2.48-6.34];
po0.01), those who attended POP patients (OR=8.58
[2.53-29.08]; po0.01), and those with a high volume of
cases (OR=3.75[2.14-6.59]; po0.01) were more likely to
prescribe VPs than those without such experience. After
adjusting for confounding factors, all the variables remained
significantly associated with the prescription of VPs in the
final model (except the variable attending POP patients);
relatively young physicians were twice as likely to prescribe
VP (OR=1.97[1.00-3.91); p=0.01), as well as physicians with
a relatively high number of prolapse cases (4+) (OR=2.32
[1.21-4.47); p=0.01) and those who participated in a previous
urogynecology fellowship (OR=2.34[1.34-4.09]; po0.01). Inter-
estingly, physicians with a PhD degree were also associated
with increased odds of prescribing VPs in the multivariate
analysis (OR=1.75[1.01-7.54]; p=0.05)
’ DISCUSSION
We found that most of the gynecologists, despite knowing
the device and its use for POP treatment, did not offer or
prescribe it to their patients. Moreover, young professionals,
those with advanced degrees (PhD), those with previous
urogynecology fellowship experience and those who atten-
ded high POP volumes were associated with VP prescriptions.
Regarding the prevalence of VP prescription, the results were
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different from those in North American and European
countries, where the majority of physicians usually prescribe
this device. This is reason for concern because VPs are mini-
mally invasive devices that can be feasibly used in any region
regardless of its socioeconomic development (8). Despite
the considerable number of trained urogynecologists in this
sample, we still observed that majority did not prescribe VPs.
There are some hypotheses about this low to moderate
frequency of VP prescription. One hypothesis is the lack of
training on inserting VPs during residency. Most of the
nonprescribers reported that they did not have experience
administering VPs for their patients. Perhaps physicians
do not know how to measure the vaginal cavity to identify
the appropriate pessary for each patient. We do not have
published studies about this topic in Brazil; however, a study
in the US found that obtaining experience in pessary fitting
and formal pessary-specific didactics and working with
advanced practitioners improved residents’ confidence in
pessary use (9). Another possibility is the involvement of a
multidisciplinary team. In our service, physiotherapists work
with urogynecologists and nurses to provide assistance to
women using VPs. In the US, an e-mail survey of three
professional nursing organizations found that 86.4% of the
nurses managed pessaries in the practice setting (10); how-
ever, in the UK, doctors were significantly more involved in
pessary care than nurses or physiotherapists (11). This could
be a feasible and cost-effective option for any health care
unit, sharing the responsibilities of care for these patients.
Most of the reasons that were noted as indications for VP
use were similar to that available in the literature, such as
patients who have contraindications for surgery, regardless
of the type of VP that is chosen (7,11,12). The most frequent
devices were the ring and donut pessaries, similar to other
studies (7,11,12). An American study found that gynecolo-
gists preferred the ring because it was the easiest to use (13).
It is still unknown whether one device is superior to another;
prospective, randomized studies are necessary to address
this question.
With regard to follow-up for the cleaning and manage-
ment of VPs, most gynecologists scheduled a 4-week follow-
up appointment. In the Netherlands, the first follow-up visit
generally occurred between 6 and 12 weeks (7). There is no
evidence in the literature about the ideal or minimal follow-
up intervals after initial VP placement. Moreover, we do not
know the proportion of patients who are able to learn to
clean and replace the pessary themselves. Our local exp-
erience gives us the impression that patients prefer to return
for a follow-up visit to have their VPs cleaned and reinserted;
however, a prospective study regarding this outcome is
needed to confirm this statement.
Table 2 - Risk factors associated with pessary prescription for pelvic organ prolapse.
Variables Pessary prescription (%) Crude OR
(95%CI); p-value
Adjusted OR (95%CI);
p-value
Yes No
Age (years) 1.32 (0.99-1.74); 0.05 1.34 (0.97-1.87)
18-35 74 (52.86) 66 (47.14) 1.81 (1.03-3.21); 0.04 1.97 (1.00-3.91); 0.04
36-50 62 (50) 62 (50) 1.62 (0.91-2.90); 0.10 1.59 (0.83-3.06); 0.16
50+ 29 (38.16) 47 (61.84) Ref Ref
Sex 0.68 (0.41-1.10); 0.12 0.85 (0.48-1.50); 0.58
Female 115 (46) 135 (54)
Male 50 (55.55) 40 (44.44)
Brazilian region 1.07 (0.086-1.35); 0.52 -------------------
North 2 (33.33) 4 (66.67) Ref Ref
Northeast 29 (47.54) 32 (52.46) 1.81 (0.30-10.64); 0.51
Midwest 10 (52.63) 9 (47.37) 2.22 (0.35-15.18); 0.42
Southeast 104 (47.71) 114 (52.29) 1.82 (0.33-10.17); 0.49
South 20 (55.56) 16 (44.44) 2.5 (0.40-15.43); 0.32
Education level 1.27 (0.95-1.70); 0.10
Medical residency 115 (46) 135 (54) Ref Ref
Master’s degree (e.g., MsC, MPH) 29 (51.79) 27 (48.21) 1.26 (0.71-2.25); 0.43 1.04 (0.53-2.03); 0.93
Doctorate degree (e.g., PhD, DsC) 15 (65.22) 8 (34.78) 2.20 (0.90-5.38); 0.08 2.75 (1.01-7.54); 0.0.05
Postdoctorate research fellow 6 (54.54) 5 (45.46) 1.41 (0.42-4.74); 0.58 0.63 (0.11-5.51); 0.50
Type of department where the physician works*
Private office 109 (50.70) 106 (49.30) 1.24 (0.80-1.94); 0.32
Private hospital 66 (51.97) 61 (48.03) 1.23 (0.79-1.91); 0.35
Public hospital 81 (52.60) 73 (47.40) 1.33 (0.86-2.04); 0.18
Academic hospital 66 (54.10) 56 (45.90) 1.40 (0.90-2.19); 0.15
Clinical fellowship in urogynecology 3.97 (2.48-6.34); o0.01 2.34 (1.34-4.09); o0.01
Yes 127 (61.35) 80 (38.65)
No 38 (28.57) 95 (71.43)
Do you attend clinical cases of pelvic
organ prolapse?
8.58 (2.53-29.08); o0.01 0.69 (0.10-4.54); 0.70
Yes 162 (51.76) 151 (48.24)
No 3 (11.11) 24 (88.89)
How many cases of genital prolapse
do you attend per week?
1.53 (1.28-1.83); o0.01 1.29 (1.05-1.59); 0.02
1 38 (36.89) 65 (63.11) Ref Ref
2 31 (46.97) 35 (53.03) 1.52 (0.81-2.84); 0.19 1.11 (0.56-2.19); 0.76
3 16 (48.48) 17 (51.52) 1.61 (0.73-3.55); 0.24 1.14 (0.49-2.65); 0.76
4+ 79 (68.70) 36 (31.30) 3.75 (2.14-6.59); o0.01 2.32 (1.21-4.47); 0.01
*Dummy variables.
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Regarding replacing the VP, most of the gynecologists
performed replacement after one year of use or when the
patient requested it. This is probably related to the fear
of complications. We do not have a standardized recom-
mendation about whether to replace the device or not and
when should we do so. Among physicians who prescribe VPs,
increased vaginal discharge was the most common complica-
tion reported, similar to results published in the literature (14).
To our knowledge, this is the first study about pessary
use practices for POP considering gynecologists in a Latin
American country, such as Brazil. Moreover, we believe that
the external validity was not impaired because most of our
sampling was conducted at a general obstetrics and gyne-
cology meeting, accurately representing reality. However,
there were limitations; they were mostly related to survey
biases (response bias, social desirability bias) and possible
selection bias (most of the participants participated in a
clinical fellowship in urogynecology), meaning that the
frequency may be lower than the value we found among
the general practitioners. However, we believe these results
will have good external validity because it is hypothesized
that practitioners who attend meetings have more knowl-
edge about medical treatments regardless of their specialty.
Thus, these physicians are probably updated on the medical
literature.
In conclusion, there was a low rate of VP prescription
despite the majority of the doctors knowing about the device
and its use for POP because there was a lack of experience in
VP use. The results of this study emphasize the importance
of training and education among gynecologists, mainly
during residency, about other POP treatment options; this
will empower patients with knowledge regarding all their
possibilities, allowing them to choose the best treatment
for their particular situation. A feasible and more complete
scenario would be working with a multidisciplinary team,
where physicians along with nurses and/or physiotherapists
could share the task of identifying these patients.
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